id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-D-0027-0016,FDA,FDA-2005-D-0027,"Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry and Food and Drug Administration Staff - Final Guidance",Other,Guidance,2022-10-07T04:00:00Z,2022,10,2022-10-07T04:00:00Z,,2024-11-07T00:43:10Z,,1,0,09000064853d399e
FDA-2005-D-0027-0015,FDA,FDA-2005-D-0027,"Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry and Food and Drug Administration Staff; and Procedures for Handling Post-Approval Studies Imposed by Premarket Approval Application Order; Guidance for Industry and Food and Drug Administration Staff; Availability - Final Guidance",Notice,Notice of Availability,2022-10-07T04:00:00Z,2022,10,2022-10-07T04:00:00Z,,2022-10-07T19:13:39Z,2022-21832,0,0,09000064853d399d
FDA-2005-D-0027-0014,FDA,FDA-2005-D-0027,Procedures for Handling Post-Approval Studies Imposed by PMA Orders,Other,Guidance,2022-10-06T04:00:00Z,2022,10,2022-10-06T04:00:00Z,,2022-10-06T20:12:10Z,,0,0,09000064853c7767
FDA-2005-D-0027-0013,FDA,FDA-2005-D-0027,Procedures for Handling Post-Approval Studies Imposed by PMA Order,Other,Guidance,2022-10-06T04:00:00Z,2022,10,2022-10-06T04:00:00Z,,2024-11-06T23:35:55Z,,1,0,09000064845bf520